Colorectal cancer, a major public health concern in China, is expected to become the second most common form of cancer there by 2028, behind only lung cancer. The treatment of metastatic colorectal cancer is dominated by chemotherapy regimens prescribed in combination with angiogenesis inhibitors and EGFR inhibitors. Unlike in the major markets, only a few targeted therapies have been available for the treatment of colorectal cancer in China, including Roche’s Avastin and BMS’s Erbitux. However, the growing uptake of two recently launched angiogenesis inhibitors—Bayer’s Stivarga and Chi-Med’s Elunate—and the anticipated launch and uptake of targeted therapies—Amgen’s Vectibix, Sanofi’s Zaltrap, and Chia Tai Tianqing Pharmaceuticals’ Focus V—will lead to significant growth in China’s colorectal cancer market during the 2018-2028 forecast period. Despite the availability of novel targeted agents, the unmet need for additional, effective targeted therapies for colorectal cancer will remain high in China, representing a lucrative opportunity for drug developers.

  • How large is China’s drug-treatable colorectal cancer population, and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s colorectal cancer market and why? What are interviewed experts’ insights on current treatment options? Which clinical needs remain unfulfilled?
  • What are the key market access considerations for key therapies in the colorectal cancer pipeline in China? What sales / uptake could they secure in colorectal cancer? What are interviewed experts’ opinions on the key emerging therapies?
  • What are the key drivers and constraints in China’s colorectal cancer market, and how will the market evolve over the forecast period?


China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Release date

September 2019



Primary Research

Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.


Diagnosed prevalence of colorectal cancer by BRAFand RAS biomarker status and by disease stage. Clinically and market relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient shares of key colorectal cancer therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/PR: 8 drugs; Phase II: > 10 drugs; coverage of select early-phase products.

Table of contents

  • Colorectal Cancer - China In-Depth - China
    • China In-Depth: Colorectal Cancer

Author(s): Amardeep Singh, M.Pharma; Akash Saini, PhD; Narendra Parihar

Amardeep is a Senior Analyst in Decision Resources Group’s China-In-Depth team. In this role, he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market. Prior to joining Decision Resources Group, Amardeep has worked with WNS Global Services for more than 5 years, where he worked in commercial analytics team to support Respiratory franchise of one of the top ten global pharma company. He also worked with GlobalData for years and authored the syndicated reports on Rare, Ophthalmology and Psychiatric disorders. He earned a master’s degree in Pharmaceutical Management from University of Delhi and Bachelor of Pharmacy from Guru Gobind Singh Indraprastha University (GGSIPU), New Delhi.  

Akash is a manager on the China In-Depth team at Decision Resources Group (DRG). Since 2016, he has specialized in market research and competitive intelligence in a range of diseases in diverse therapeutic areas, including non-small-cell lung cancer (NSCLC), amyotrophic lateral sclerosis (ALS), idiopathic pulmonary fibrosis (IPF), and rheumatoid arthritis (RA) at DRG. He has authored various research and analysis reports for the , EU5, and China markets, leveraging primary and secondary market research and real-world evidence. Prior to joining DRG, Akash was a postdoctoral fellow at the University of Massachusetts Medical School. He holds a from the International Centre for Genetic Engineering and Biotechnology in New Delhi and an from Jawaharlal Nehru University in New Delhi.

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

Related Reports

Colorectal Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU) Previously Treated RAS and BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treat...

View Details

Colorectal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Targeted therapies and various biomarkers (e.g., RAS,

View Details

Colorectal Cancer | Epidemiology | Mature Markets

DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of c...

View Details

Colorectal Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are

View Details